ABSTRACT
After completion of the therapy and confirmation of adequate tissue distribution of the destructive agent, the patient is monitored for both site-specific and systemic complications. Broad-spectrum antibiotics are continued for several days. Combination therapies with systemic or regional chemotherapy or radiotherapy can be considered at this point. Serum or urine biochemical tumor markers are periodically used to assess treatment. CT, magnetic resonance imaging (MRI), and less frequently, US may be used to evaluate the results of therapy. US-guided biopsy has proved definitive in assessing if viable tumor is still present.
